Skip to main navigation menu Skip to main content Skip to site footer

No. 4 (2024)

PRACTICE

Diagnostics and Therapy of Tardive Dyskinesias (Syndrome)

https://doi.org/10.21265/PSYPH.2024.60.92.008

Published 2024-12-30

  • D.V. Pervaya

D.V. Pervaya
Mindset Clinic of Psychiatry and Psychotherapy

Abstract

Tardive dyskinesias (TD) are a burden in the lives of the patients, because they are, in most cases, irreversible. The prevalence of TD is 25,3 % with lower rates observed in patients taking second-generation antipsychotics than in those taking first-generation antipsychotics. The emergence of new drugs from the class of vesicular monoamine transporter type 2 (VMAT-2) inhibitors has created an opportunity to manage this syndrome. A representative of this class is tetrabenazine, the only drug from this group available in Russia. This article presents an overview of the experience of diagnostics and prophylactics of TD and an analysis of the therapy of this syndrome based on four studies, including two randomized control trials (RCTs), one retrospective study, and one systematic review with meta-analysis. The publications were collected in July 2024 from the databases: PubMed, Web of Science и Google Scholar. Literature sources were searched using a combination of keywords: tetrabenazine, vesicular monoamine transporter 2 inhibitors, VMAT-2, treatment of tardive dyskinesias, treatment of tardive syndrome, tardive dyskinesias + tetrabenazine. The search was conducted in English and Russian using keyword synonyms, as well as the MeSH for PubMed. Initially, 72 studies were found. It was revealed that one of the most important stages of TD therapy is the prevention of this syndrome by adjusting modifiable risk factors. Tetrabenazine can be used in addition to the main therapy as the third-line agent. Studies examining tetrabenazine are scarce. According to the two RCTs, tetrabenazine intake was associated with a reduction in TD symptoms, and a retrospective study on a small sample of patients also showed improvement by the CGI scale. All the studies conducted had significant methodological limitations and a high likelihood of systematic bias. No evidence base was found for other treatment options. The review includes information on the diagnosis and classification of TD. Based on this study, the following conclusions were made: TD prevention should be carried out prior to each case of antipsychotic prescription; there is an algorithm for the treatment of TD, in which tetrabenazine is the third-line agent and can be used as an additional therapy for TD management.

Keywords

tetrabenazine, vesicular monoamine transporter 2 inhibitors, VMAT-2, treatment of tardive dyskinesias, treatment of tardive syndrome, tardive dyskinesias tetrabenazine

PDF (Русский)

References

  1. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen // Nervenarzt. – 1957. – Vol. 28 (12). – Pр. 550–553.
  2. Sigwald J., Bouttier D., Raymondeaud C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a evelution prolongee secondaire a un traitement par les neuroleptiQues // Rev Neurol. – 1959. – Vol. 100. – Pр. 751–755.
  3. Wertheimer J. Syndromes extra-pyramidaux permanents consеcutifs а` l’administration prolongеe de neuroleptiques: dissertation. – Universitе de Lausanne, Facultе de mеdecine, 1963.
  4. Savitt D., Jankovic J. Tardive syndromes // Journal of the neurological sciences. – 2018. – Vol. 389. – Pр. 35–42. – https://doi.org/doi: 10.1016/j.jns.2018.02.005
  5. Salem H. et al. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management // Expert Review of Neurotherapeutics. – 2017. – Vol. 17 (9). – Pр. 883– 894. – https://doi.org/10.1080/14737175.2017.1361322
  6. Crane G.E. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature // American Journal of Psychiatry. – 1968. – Vol. 124 (8). – Pр. 40–48. – https://doi.org/10.1176/ajp.124.8S.40
  7. Мосолов С.Н. Психозы дофаминовой гиперчувствительности на современном этапе антипсихотической фармакотерапии шизофрении : что нужно знать практикующему врачу // Современная терапия психических расстройств. – 2018. – № 4. – С. 41–49. –https://doi.org/10.21265/PSYPH.2018.47.21794
  8. Baminiwatta A., Correll C.U. Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications // Frontiers in Psychiatry. – 2023. – Vol. 14. – Pр. 1–44. – https://doi.org/10.3389/fpsyt.2023.1194222
  9. Chouinard G., Jones, D. B., Lawrence A. Neuroleptic-induced supersensitivity psychosis // Tardive Dyskinesia and Related Involuntary Movement Disorders. John Wright PSG of Boston, Massachusetts. – 1978. – Pр. 109–115.
  10. DSM-5 [Electronic resource]. URL: https://archive.org/stream/DSM5Eng/DSM@5%20eng_djvu.txt (accessed October 12, 2024).
  11. Frei K. Tardive dyskinesia: Who gets it and why // Parkinsonism and Related Disorders. – Vol. 59. – Pр. 151–154. – https://doi.org/10.1016/j.parkreldis.2018.11.017
  12. Carbon M., Hsieh C.H., Kane J. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis // J Clin Psychiatry. – 2017. – Vol. 78 (3). – Art. 20738. – https://doi.org/10.4088/JCP.16r10832
  13. Потанин С.С., Антонович Б.А., Сайфулина А.М. Алгоритм биологической терапии поздней дискинезии // Современная терапия психических расстройств. – 2021. – С. 41–49. – https://doi.org/10.21265/PSYPH.2021.24.99.005
  14. Jain R., Correll C.U. Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis: (Academic Hightlights) // J Clin Psychiatry. – 2018. – Vol. 79 (2). – Pр. 16– 23. – https://doi.org/10.4088/JCP.nu17034ah1c
  15. Widschwendter C.G., Hofer A. Antipsychotic-induced tardive dyskinesia: Update on epi demiology and management // Current Opinion in Psychiatry. – 2019. – Vol. 32 (3). – Pр. 179–184. – https://doi.org/10.1097/YCO.0000000000000491
  16. Jackson R. et al. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia // Journal of Clinical Psychiatry. – 2022. – Vol. 84 (1). – Р. 22cs14563. – https://doi.org/10.4088/JCP.22cs14563
  17. ICD-10 [Electronic resource]. URL: https://icd.who.int/browse10/2019/en (accessed October 12, 2024).
  18. ICD-11 [Electronic resource]. URL: https://icd.who.int/en (accessed October 12, 2024).
  19. Citrome L., Dufresne R., Dyrud J.M. Tardive Dyskinesia: Minimizing Risk and Improving Outcomes in Schizophrenia and Other Disorders // The American Journal Of Managed Care. – 2007. – P. 1-12.
  20. Keepers G.A. et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia // American Journal of Psychiatry. – 2020. – Vol. 177 (9). – Pр. 868–872. – https://doi.org/10.1176/appi.ajp.2020.177901
  21. Lane R., Glazer W., Hansen T. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale // The Journal of Nervous and Mental disease. – 1985. – Vol. 173 (6). – Pр. 353–357. – https://doi.org/10.1097/00005053-198506000-00005
  22. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia // Archives of General Psychiatry. – Vol. 39 (4). – 1982. – Pр. 486–487. – https://doi.org/10.1001/archpsyc.1982.04290040080014
  23. Carbon M. et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis // World Psychiatry. – 2018. – Vol. 17 (3). – Pр. 330–340. – https://doi.org/10.1002/wps.20579
  24. Patterson-Lomba O., Ayyagari R., Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: A retrospective data analysis // BMC Neurology. – 2019. – Vol. 19 (1). – Pр. 1–10. – https://doi.org/10.1186/s12883-019-1385-4
  25. Solmi M. et al. Clinical risk factors for the development of tardive dyskinesia // Journal of the Neurological Sciences. – 2018. – Vol. 389. – Pp. 21–27.
  26. Strassnig M., Rosenfeld A., Harvey P.D. Tardive dyskinesia: Motor system impairments, cognition and everyday functioning // CNS Spectrums. – 2018. – Vol. 23 (6). – Pр. 370– 377. – https://doi.org/10.1017/S1092852917000542
  27. Jackson R. et al. Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations // Neuropsychiatric Disease and Treatment. – 2021. – Vol. 17. – Pр. 1589–1597. – https://doi.org/10.2147/NDT.S310605
  28. Ondo W.G., Hanna P.A., Jankovic J. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol // American Journal of Psychiatry. – 1999. – Vol. 156 (8). – P. 1279–1281. – https://doi.org/10.1176/ajp.156.8.1279
  29. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study // Annals of Neurology. – 1982. – Vol. 11 (1). – Pр. 41–47. – https://doi.org/10.1002/ana.410110108
  30. Paleacu D., et al. Tetrabenazine treatment in movement disorders // Clinical Neuropharmacology. – 2004. – Vol. 27 (5). – Pр. 230–233. – https://doi.org/10.1097/01.wnf.0000136892.24629.96
  31. Ricciardi L. et al. Treatment Recommendations for Tardive Dyskinesia // Canadian Journal of Psychiatry. – 2019. – Vol. 64 (6). – Pр. 388–399. – https://doi.org/10.1177/0706743719828968
  32. Bernstein A.I., Stout K.A., Miller G.W. The vesicular monoamine transporter 2: An underexplored pharmacological target // Neurochemistry International. – 2014. – Vol. 73. – Pр. 89–97. – https://doi.org/10.1016/j.neuint.2013.12.003
  33. Correll C.U., Carbon M. A new class of VMAT-2 inhibitors for tardive dyskinesia // The Lancet Psychiatry. – Vol. 4 (8). – Pр. 574–575. – https://doi.org/10.1016/S2215-0366(17)30279-1
  34. Solmi M., et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: A systematic review and meta-analysis of randomized controlled trials // Drug Design, Development and Therapy. – 2018. – Vol. 12. – Pр. 1215–1238. –https://doi.org/10.2147/DDDT.S133205
  35. Connolly A. et al. Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis // Psychopharmacology. – 2024. – Vol. 241 (2). – Pр. 225–241. – https://doi.org/10.1007/s00213-023-06488-3

Downloads

Download data is not yet available.